Vascular hyporeactivity persists despite increased contractility after longterm administration of isosorbide dinitrate in portal hypertensive rats

Journal of Hepatology

Volumn 28, Issue 6, 1998, Pages 1037-1044

  Huang, Yi Tsau ^a   Lin, Han Chieh ^a,b   Tsai, Ju Fen ^a   Hou, Ming Chih ^a,b   Lee, Shou Dong ^a,b   Hong, Chuang Ye ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Contractile response; Isosorbide dinitrate; Phenylephrine; Portal hypertension; Superior mesenteric artery

Indexed keywords

ISOSORBIDE DINITRATE; PHENYLEPHRINE; POTASSIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; ESOPHAGUS VARICES BLEEDING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; RAT; SUPERIOR MESENTERIC ARTERY; VEIN LIGATION;

EID: 0032102881     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80354-1     Document Type: Article

References (38)

1. Genecin P, Groszmann RJ. The biology of portal hypertension. Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. 3rd ed. The Liver: Biology and Pathobiology. 1994;1327-1341 Raven Press, New York.
2. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther. 61:1994;65-107.
3. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 22:1995;332-354.
4. Blei AT, Granger D, Fung H-L, Groszmann RJ. Organic nitrates in portal hypertension. Eur Heart J. 9:1988;205-211. (Suppl A).
5. Moreau R, Lebrec D. Nitrovasodilators and portal hypertension. J Hepatol. 10:1990;263-267.
6. Jones AL, Hayes PC. Organic nitrates in portal hypertension. Am J Gastroenterol. 89:1994;7-14.
7. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis. 6:1986;287-298.
8. Karatapanis S, McCormick PA, Kakad S, Chin JKT, Islam M, Jeremy J, et al. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology. 20:1994;1516-1521.
9. 1-adrenoceptors of portal hypertensive rats. Br J Pharmacol. 111:1994;439-444.
10. Mesh CL, Joh T, Korthuis RJ, Granger DN, Benoit JN. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology. 100:1991;916-921.
11. Murray BM, Paller MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats: evidence for a post-receptor in angiotensin action. Circ Res. 57:1985;424-431.
12. Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol. 240:1981;G371-G375.
13. Huang Y-T, Wang G-F, Yang MCM, Chang S-P, Lin H-C, Hong C-Y. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. J Pharmacol Exp Ther. 278:1996;535-541.
14. Huang Y-T, Tsai J-F, Liu T-B, Hong C-Y, Yang MC-M, Lin H-C. Chronic administration of octreotide increases vascular responsiveness in rats with portal hypertension. Clin Sci. 91:1996;601-606.
15. Huang Y-T, Lin H-C, Tsai J-F, Hou M-C, Hong C-Y. Chronic administration of propanolol improves vascular contractile responsiveness in portal hypertensive rats. Eur J Clin Invest. 27:1997;550-555.
16. Weigert AL, Martin P-Y, Niederberger M, Higa EMS, McMurty IF, Gines P, et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aorta of cirrhotic rats. Hepatology. 22:1995;1856-1862.
17. 1-adrenoceptor in tail artery and aorta from spontaneously hypertensive and Wistar-Kyoto rats. J Cardiovasc Pharmacol. 22:1993;191-197.
18. Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 104:1993;1460-1465.
19. Folkow B. The structural factor in hypertension with special emphasis on the altered geometric design of the systemic resistance arteries. Laragh JH, Brenner BM. 2nd ed. Hypertension: Pathophysiology, Diagnosis and Management. 1995;481-502 Raven Press, New York.
20. Sieber CC, Lee F-Y, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats. Hepatology. 23:1996;1218-1223.
21. 1-adrenoceptors by nitroglycerin. Acta Pharmacol Toxicol. 55:1984;73-77.
22. Molina CR, Andresen JW, Rapoport RM, Waldman S, Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol. 10:1987;371-378.
23. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA. 92:1995;5244-5248.
24. Vatner SF, Pagani M, Rutherford JD, Millard RW, Manders WT. Effects of nitroglycerin on cardiac function and regional blood flow distribution in conscious dogs. Am J Physiol. 234:1978;H244-H252.
25. Wu Z-Y, Benoit JN. Nonreceptor-mediated intestinal vasoconstriction in portal hypertensive rats. Am J Physiol. 267:1994;H370-H375.
26. Sogni P, Sabry S, Moreau R, Gadano A, Lebrec D, Dinh-Xuan AT. Hyporeactivity of messenteric resistance arteries in portal hypertensive rats. J Hepatol. 24:1996;487-490.
27. Huang Y-T, Yu P-C, Lee M-F, Lin H-C, Hong C-Y, Yang MCM. Decreased vascular contractile and inositol phosphate responses inportal hypertensive rats. Can J Physiol Pharmacol. 73:1995;378-382.
28. Lin H-C, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol. 13:1991;213-219.
29. ω-Nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 105:1993;1464-1470.
30. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol. 262:1992;G996-G1001.
31. Michielson PP, Boeckxstaens GE, Sys SU, Herman AG, Pelckmans PA. Role of nitric oxide in hyporeactivity to noradrenaline of isolated aortic rings in portal hypertensive rats. Eur J Pharmacol. 273:1995;167-174.
32. Ortiz MC, Fortepiani LA, Martinez C, Atucha NM, Garcia-Estan J. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Clin Sci. 91:1996;733-738.
33. Gadano AC, Sogni P, Yang S, Cailmail S, Moreau R, Nepveux, et al. Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol. 26:1997;678-686.
34. Heinemann A, Stauber RE. The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats. Eur J Pharmacol. 278:1995;87-90.
35. Ralevic V, Mathie R, Moore KP, Burnstock G. Vascular responsiveness of the rat mesenteric arterial bed in cirrhosis. Br J Pharmacol. 118:1996;435-441.
36. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology. 20:1994;1343-1350.
37. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and corss-tolerance. J Clin Invest. 95:1995;187-194.
38. Colombato LA, Robin M, Pomier-Layrargues G, Huet P-M. Animal models of portal hypertension. Holstege A, Hahn EG, Scholmerich J. Portal Hypertension. 1995;3-14 Kluwer Academic Publishers, London.